Baseline Predictors of Disease Activity in Patients with CIS Treated with Interferon beta-1b in the BENEFIT 11 Trial (P2.121)
Conclusion: Analyses of patients after 11 years identified a number of baseline demographic, MRI, and clinical variables that predicted longer-term disease outcomes. Among other factors, assignment to earlier treatment with interferon beta-1b was associated with longer time to CDMS.Disclosure: MS Freedman has received compensation from Bayer HealthCare, Biogen Idec, EMD Canada, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva Canada Innovation for consulting services. Dr. Kappos's institution (University Hospital Basel) has received royalty payments from Neurostatus Systems GmbH. Dr. Edan has nothing to disclose. ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Freedman, M., Kappos, L., Edan, G., Montalban, X., Hartung, H., Hemmer, B., Fox, E., Barkhof, F., Schippling, S., Koelbach, R., Pleimes, D., Suarez, G., Wicklein, E.-M. Tags: MS and CNS Inflammatory Disease: Treatment Outcome Measures Source Type: research
Is Health-Related Quality of Life an Important Evaluation Criterion in Drug Development of Multiple Sclerosis (MS) Products? A Review of Labels of MS Products Approved the FDA and the EMA (P2.124)
Conclusions: HRQL is not considered as a key endpoint in the evaluation of MS products. A patient-focused drug development initiative in MS could be helpful to enhance development and use of HRQL MS-specific measures in clinical trials.Disclosure: Dr. Acquadro has received personal compensation for activities with Mapi Pharma as a consultant. Dr. Perret has nothing to disclose. Dr. Regnault has received personal compensation for activities with Mapi. (Source: Neurology)
Source: Neurology - April 3, 2016 Category: Neurology Authors: Acquadro, C., Perret, C., Regnault, A. Tags: MS and CNS Inflammatory Disease: Treatment Outcome Measures Source Type: research
A 10-year follow-up of the European multicenter trial of interferon {beta}-1b in secondary-progressive multiple sclerosis
Conclusions:
The results from this analysis did not provide convincing evidence to support a favorable long-term outcome in those patients allocated IFNB-1b during the RCT, in our SPMS cohort. The progressive stage of the disease remains largely unpredictable by clinical and conventional MRI measures, so better prognostic markers are needed. (Source: Multiple Sclerosis)
Source: Multiple Sclerosis - March 17, 2016 Category: Neurology Authors: Kuhle, J., Hardmeier, M., Disanto, G., Gugleta, K., Ecsedi, M., Lienert, C., Amato, M., Baum, K., Buttmann, M., Bayas, A., Brassat, D., Brochet, B., Confavreux, C., Edan, G., Färkkilä, M., Fredrikson, S., Frontoni, M., DHooghe, M., Hutchin Tags: Original Research Papers Source Type: research
Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder
Publication date: Available online 16 March 2016 Source:Multiple Sclerosis and Related Disorders Author(s): Fumihito Yoshii, Yusuke Moriya, Tomohide Ohnuki, Masafuchi Ryo, Wakoh Takahashi Fingolimod (FTY720) is used for reducing the annualized relapse rate and slowing progression of neurological disability in relapsing-remitting forms of multiple sclerosis (MS). However, its safety is not confirmed in patients with neuromyelitis optica spectrum disorder (NMOSD), who characteristically have positive aquaporin-4 (AQP-4) antibody. A 54-year-old female with a relapsing-remitting course of optic neuritis and myeli...
Source: Multiple Sclerosis and Related Disorders - March 16, 2016 Category: Neurology Source Type: research
BENEFIT 11: No new safety signals with interferon beta-1b
NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial... (Source: Internal Medicine News)
Source: Internal Medicine News - March 2, 2016 Category: Internal Medicine Source Type: research
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b
Multiple sclerosis (MS) is the most common demyelinating diseases of central nervous system (CNS). Misdirected immune responses to CNS myelin antigens are considered pivotal in MS pathogenesis [1]. It is believed that interferon beta 1b (IFN-β-1b) is beneficial in the treatment of relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) as it has been shown in several clinical trials [2,3]. Even though it is assumed that the beneficial effect of IFN-β-1b is related to immunomodulation cells, the exact mechanisms of action of IFN-β-1b in MS remain unclear [4,5]. (Source: Journal o...
Source: Journal of the Neurological Sciences - February 21, 2016 Category: Neurology Authors: Marija Bosnjak Pasic, Sanja Hajnsek, Miljenko Panajatovic MPharm, Branka Vidrih, Ivan Bohacek, Snježana Miskov Tags: Letter to the Editor Source Type: research
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
CONCLUSIONS: The acquisition costs of DMF for treatment of RRMS are predicted to be partially offset by reduced costs of relapses in the Canadian healthcare system.
PMID: 26390149 [PubMed - in process] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 13, 2016 Category: Health Management Tags: J Med Econ Source Type: research
Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT (S37.002)
Conclusions: Our results, based on multiple assessments of sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity.Disclosure: Dr. Fitzgerald has nothing to disclose. Dr. Munger has nothing to disclose. Dr. Freedman has received research support from Bayer Healthcare and Genzyme. Dr. Hartung has received personal compensation for activities with from Bayer, Biogen, GeNeuro, Genzyme as speaker, committee member, consultant. Dr. Montalban has received personal compensation for activities with Actelion, Almirall, Bayer Pharmaceuticals...
Source: Neurology - February 7, 2016 Category: Neurology Authors: Fitzgerald, K., Munger, K., Freedman, M., Hartung, H., Montalban, X., Edan, G., Barkhof, F., Radue, E.-W., Kappos, L., Suarez, G., Ascherio, A. Tags: Risk Factors for Multiple Sclerosis Source Type: research
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
CONCLUSIONS: Consequently, IFNβ-1a and IFNβ-1b, applied to the culture medium, have no macroscopic teratogenic effect on embryonic development. However, in respect of morphometric measurements, IFNβ-1a and IFNβ-1b have caused growth retardation in embryo. This research related to interferon was the first study using vitro embryo culture technique, thus in our point of view, future studies which will be performed by using different doses of IFN will contribute to the literature.
PMID: 26711647 [PubMed - as supplied by publisher] (Source: Folia Morphologica)
Source: Folia Morphologica - January 12, 2016 Category: Anatomy Tags: Folia Morphol (Warsz) Source Type: research
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT ™)
Conclusion < /h3 > < p class= " a-plus-plus " > Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients ’ overall injection experience. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec5 " > < h3 class= " a-plus-plus " > Funding < /h3 > < p class= " a-plus-plus " > Bayer HealthCare Pharmaceuticals. < /p > < /span > (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 30, 2015 Category: Neurology Source Type: research
Treatment With Lopinavir/Ritonavir or Interferon-{beta}1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil [MMF], lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe d...
Source: The Journal of Infectious Diseases - November 23, 2015 Category: Infectious Diseases Authors: Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., Cai, J.-P., Chu, H., Zhou, J., Chen, H., Qin, C., Yuen, K.-Y. Tags: VIRUSES Source Type: research
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT
Conclusions:
Neither increased levels of EBV IgG antibodies, including against EBNA-1, nor elevated cotinine levels indicative of tobacco use, were associated with an increased risk of CIS conversion to MS, or MS activity or progression over a 5-year follow-up. (Source: Neurology)
Source: Neurology - November 9, 2015 Category: Neurology Authors: Munger, K. L., Fitzgerald, K. C., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalban, X., Edan, G., Barkhof, F., Suarez, G., Radue, E.-W., Sandbrink, R., Kappos, L., Pohl, C., Ascherio, A. Tags: MRI, Clinical trials Observational study (Cohort, Case control), Multiple sclerosis ARTICLE Source Type: research
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)
Conclusion
Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients’ overall injection experience.
Funding
Bayer HealthCare Pharmaceuticals. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 27, 2015 Category: Neurology Source Type: research
Cost-Effectiveness Analysis of Peginterferon Beta-1a In The Treatment of Relapsing-Remitting Multiple Sclerosis In Ireland
Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every 2 weeks) is a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) that may improve treatment adherence by reducing the frequency of administration. The pivotal ADVANCE trial showed benefits of PEG-IFN versus placebo on relapses and disability progression, but its long-term clinical and economic consequences versus other DMTs are still unknown. This analysis assessed the cost-effectiveness of PEG-IFN versus other self-injectable DMTs (Interferon beta-1a 22mcg and 44mcg three times/week, and 30mcg once/week; interferon beta-1b 250mcg ...
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: L Hernandez, S Guo, H Toro-Diaz, S Carroll, SF Syed Farooq Source Type: research
The Cost Effectiveness of Delayed-Release Dimethyl Fumarate Versus Interferon Beta-1b In A Swedish Setting
Multiple sclerosis (MS) is a neurodegenerative and demyelinating disease of the central nervous system leading to impaired nerve impulse conduction with concomitant symptoms such as weakness in limbs, muscle stiffness or spasms, paralysis, problems with vision, fatigue and cognitive changes. Current disease modifying therapies indicated for first-line treatment of relapsing-remitting MS (RRMS) in Sweden are injection therapies including beta interferons and glatiramer acetate, and the two recently approved oral treatments delayed-relase dimethyl fumarate (DMF; also known as gastro-resistant DMF) and teriflunomide. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: D Granfeldt, Å Björstad, S Öhrman, I Björholt Source Type: research
